Nuvectis Pharma, Inc.·4

Jun 20, 9:50 AM ET

Mosseri Marlio Charles 4

4 · Nuvectis Pharma, Inc. · Filed Jun 20, 2025

Insider Transaction Report

Form 4
Period: 2025-06-17
Transactions
  • Purchase

    Common Stock

    2025-06-17$8.11/sh+5,399$43,7862,948,160 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-06-18$8.05/sh+28,043$225,7462,976,203 total(indirect: By Emerald Hill Ventures SARL SPF.)
Footnotes (2)
  • [F1]Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.
  • [F2]Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.91 to $8.11. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Documents

1 file
  • 4
    tm2518418-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT